

**PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER**  
**Rules 8.1 and 8.2 of the Takeover Code (the "Code")**

**1. KEY INFORMATION**

<b>(a) Full name of discloser:</b>	Oxford Biomedica plc ("OXB")
<b>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):</b> <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
<b>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:</b> <i>Use a separate form for each offeror/offeree</i>	Oxford Biomedica plc
<b>(d) Is the discloser the offeror or the offeree?</b>	Offeree
<b>(e) Date position held:</b> <i>The latest practicable date prior to the disclosure</i>	26 January 2026
<b>(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?</b> <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

**2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE**

*If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.*

**(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates**

Class of relevant security:	Ordinary Shares of 50p each			
	Interests		Short positions	
	Number	%	Number	%
<b>(1) Relevant securities owned and/or controlled:</b>	Nil	Nil	Nil	Nil
<b>(2) Cash-settled derivatives:</b>	Nil	Nil	Nil	Nil
<b>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</b>	Nil	Nil	Nil	Nil
<b>TOTAL:</b>	Nil	Nil	Nil	Nil

*All interests and all short positions should be disclosed.*

*Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).*

*Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).*

**(b) Rights to subscribe for new securities**

Class of relevant security in relation to	None
---	------

which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:	None
---	------

### 3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

#### Interests of Directors

OXB ordinary shares held by directors of OXB and their close relatives and related trusts

Director	Number of OXB ordinary shares held	Percentage of total issued share capital*
Dr. Roch D oliveux	438,805	0.36%
Dr. Frank Mathias	20,000	0.01%
Professor Dame Kay Davies	1,000	0.00%
Namrata P Patel	9,170	0.00%
Dr. Heather Preston	35,862	0.02%
<b>Total</b>	<b>504,837</b>	<b>0.41%</b>

\*Percentages have been given to two decimal places.

Interests held as options or awards by directors of OXB in ordinary shares of OXB

Director	Share plan	Grant date	Number of OXB ordinary shares in respect of which options granted / subject to award	Exercise price (per share) (£)	Vesting Date	Date of expiry of exercise period
Dr. Frank Mathias	2015 Long Term Incentive Plan*	04/10/2023	323,178	0.00	04/10/2026	04/10/2033
	2024 Long Term Incentive Plan*	03/10/2024	257,113	0.00	03/10/2027	03/10/2034
	2024 Long Term Incentive Plan*	16/05/2025	350,204	0.00	16/05/2028	16/05/2035
	2024 Deferred Bonus Plan**	16/05/2025	70,803	0.00	T1 16/05/2026 T2 16/05/2027 T3 16/05/2028	16/05/2035
Dr. Lucinda Crabtree	2024 Long Term Incentive Plan*	03/10/2024	170,113	0.00	03/10/2027	03/10/2034
	2024 Long Term Incentive Plan*	16/05/2025	201,095	0.00	16/05/2028	16/05/2035
	2024 Deferred Bonus Plan**	16/05/2025	15,733	0.00	T1 16/05/2026 T2 16/05/2027 T3 16/05/2028	16/05/2035

\* The vesting of the 2015 and 2024 Long Term Incentive Plan award is subject to the achievement of performance conditions and a two year holding period following the vesting date.

\*\* Deferred Bonus Plan vests in three equal tranches.

---

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

#### 4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

*Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"*

None.

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

- (i) the voting rights of any relevant securities under any option; or
- (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

*If there are no such agreements, arrangements or understandings, state "none"*

None.

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	27 January 2026
Contact name:	Natalie Walter, Chief Legal Officer and Group Company Secretary
Telephone number:	+44 (0) 1865 783 000

*Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.*

*The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.*

*The Code can be viewed on the Panel's website at [www.thetakeoverpanel.org.uk](http://www.thetakeoverpanel.org.uk).*

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FEEEADFXAAXKEFA